Scott Harper, Ph.D., Chief Scientific Advisor of Armatus Bio, Inc., is a molecular biologist with more than two decades of spearheading innovation in gene therapy, currently serving as a Principal Investigator at Nationwide Children’s Hospital Center for Gene Therapy. Dr. Harper has been awarded 15 patents with more than 30 pending. Prior to his work at Nationwide Children’s Hospital, Dr. Harper developed and patented the first RNAi-based gene therapies for dominant neurodegenerative diseases, which was licensed by Spark Therapeutics. As a graduate student, Dr. Harper co-invented and patented ΔR4-R23 micro-dystrophin, the centerpiece of Sarepta Therapeutics’ Duchenne muscular dystrophy gene therapy product. Dr. Harper received the 2014 American Society of Gene and Cell Therapy Outstanding New Investigator award.
Dr. Harper currently serves as a Scientific Advisory Board Member of the Charcot-Marie-Tooth Association and is a standing member of the NIH Neurological Sciences and Disorders B (NSD-B) Study Section. Dr. Harper is currently Chair of the ASGCT RNAi and Oligonucleotide Therapy Committee and a program committee member of the FSHD Society International Research Congress. He completed his post-doctoral work at the University of Iowa College of Medicine, earned his Ph.D. in Cellular and Molecular Biology from the University of Michigan, and his B.S. in Biology from Saginaw Valley State University (Summa cum laude).